February 7, 2024 11:00 AM EST
News Briefing

Jaz­z's KRAS deal with Redx; Al­to Neu­ro­science up­sizes IPO

Jaimy Lee

Deputy Editor

Plus, news about Pep­Gen and Jasper Ther­a­peu­tics:

Jazz Phar­ma­ceu­ti­cals buys Redx Phar­ma’s KRAS in­hibitors: The com­pa­ny is pay­ing Redx $10 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times